Core Viewpoint - The AI Fund for Health Industry Flexible Allocation Mixed A/B (000727) reported a profit of 179 million yuan in Q2 2025, with a net asset value growth rate of 8.97% for the period [2] Fund Performance - As of July 17, the fund's unit net value was 2.661 yuan, with a recent three-month growth rate of 15.00%, ranking 108 out of 138 comparable funds [3] - The fund's six-month growth rate was 16.45%, ranking 117 out of 138, and the one-year growth rate was 19.86%, ranking 107 out of 133 [3] - Over the past three years, the fund's growth rate was -9.89%, ranking 64 out of 106 [3] Risk and Return Metrics - The fund's Sharpe ratio over the past three years was 0.1159, ranking 48 out of 105 comparable funds [8] - The maximum drawdown over the past three years was 45.79%, with the highest quarterly drawdown occurring in Q1 2024 at 26.05% [11] Investment Strategy - The fund focuses on selecting sectors and stocks with good growth potential and relatively low valuations, aligning with the structural upgrades in China's pharmaceutical industry and the recovery of medical demand [2] - Key investment areas include innovation-driven industry upgrades, import substitution, and recovery in hospital medical services, with a focus on innovative drugs, medical devices, and low price-to-book (PB) assets [2] Fund Composition - As of June 30, the fund maintained an average stock position of 92.67% over the past three years, with a peak of 94.13% at the end of Q1 2024 [14] - The fund's total assets reached 2.074 billion yuan as of the end of Q2 2025 [15] - The top ten holdings include Yixin Hall, Aibo Medical, Sanyou Medical, Jianzhijia, Kaili Medical, Sunshine Nuohuo, Dongfang Biological, Puri Eye Hospital, Meihao Medical, and Meinian Health [18]

Core Viewpoint - The AI Fund, Rongtong Xinxin Growth Mixed A, reported a profit of 35.4486 million yuan for Q2 2025, with a net value growth rate of 12.82% and a fund size of 400 million yuan as of the end of Q2 2025 [2][15]. Fund Performance - As of July 17, 2025, the fund's one-year cumulative net value growth rate was 48.74%, ranking 50 out of 133 comparable funds [3]. - The fund's three-month net value growth rate was 21.94%, ranking 84 out of 138 comparable funds, while the six-month growth rate was 29.74%, ranking 86 out of 138 [3]. - The fund's three-year Sharpe ratio was 0.4914, ranking 12 out of 105 comparable funds [8]. Investment Strategy - The fund adheres to a contrarian investment style, focusing on sectors and stocks with good growth potential and relatively low valuations, while adjusting the portfolio structure as needed [2]. - The investment direction emphasizes domestic demand and technology, with a focus on opportunities arising from China's economic transformation and recovery [2]. - The fund is optimistic about investment opportunities in the pharmaceutical sector, particularly in the context of aging demographics, as well as in innovative drugs and high-end manufacturing with global competitive advantages [2]. Portfolio Composition - As of June 30, 2025, the fund's average stock position over the past three years was 92.67%, with a peak of 94.34% at the end of H1 2025 [13]. - The top ten holdings of the fund include companies such as Aibo Medical, Gushengtang, and Sanyou Medical, indicating a strong focus on the healthcare sector [18]. Risk Metrics - The fund's maximum drawdown over the past three years was 38.36%, ranking 59 out of 105 comparable funds, with the largest single-quarter drawdown occurring in Q1 2024 at 27.81% [10].

Core Insights - The report highlights the significant growth potential in the measurement and calibration industry, driven by new policies aimed at enhancing manufacturing capabilities in China [6][7][8] - The renewable energy sector, particularly in electric power equipment, is poised for growth due to supportive policies in the UK and increasing demand for energy storage solutions [13] - The pharmaceutical industry is recommended for investment, focusing on innovative drugs and their supply chains, with strong support from health insurance reforms [14] Industry and Company Analysis - **Measurement and Calibration Industry**: The first policy document from the Ministry of Industry and Information Technology emphasizes the need for precise measurement to drive innovation in manufacturing. This includes establishing a service network and digital transformation paths, with a focus on high-level calibration institutions and digital measurement software [6][7] - **Renewable Energy Sector**: The UK government has restarted subsidies for electric vehicles and charging infrastructure, indicating a robust market for energy storage systems. The report suggests focusing on companies involved in battery production and charging infrastructure, such as Ningde Times and Keda Technology [13] - **Pharmaceutical Industry**: The report continues to recommend innovative drug sectors, highlighting the recent adjustments in health insurance and commercial insurance that favor high-value innovative drugs. Companies like Kelun-Biotech and Innovent Biologics are noted for their strong potential in both domestic and international markets [14] - **Oil and Gas Sector**: China National Offshore Oil Corporation (CNOOC) has made significant advancements in oil and gas exploration, achieving record production levels in both domestic and international operations. The report anticipates continued growth in production capacity, particularly in the Stabroek block in Guyana [20][21][24]

Group 1 - The Shenzhen Supply Chain Innovation Cooperation Matching Conference was held on July 17, showcasing Shenzhen's economic vitality, innovation, urban charm, and investment potential to the world [1] - The conference featured 28 key enterprises from Shenzhen, including Stable Medical, UBTECH, Dazhu Laser, and Bettery, highlighting Shenzhen's significant position and strength in the global supply chain [1] - Shenzhen aims to become a global industrial technology innovation center by 2024, with its economic total expected to rank among the top ten cities globally, and it has maintained the top position in foreign trade scale in China for four consecutive years [1] Group 2 - The investment center of Longgang District presented its "3+4+N+AI" industrial structure, emphasizing advantages in electronic information, cross-border e-commerce, and artificial intelligence, along with the latest industrial investment policies [2] - The conference included representatives from companies like Kaili Medical, Diancao Agriculture, and Yuanrong Qihang, who shared insights on high-end intelligent medical devices, digital agriculture, and advanced intelligent driving technology [2] - The Shenzhen Municipal Council for the Promotion of International Trade will continue to build bridges between government and enterprises, facilitating precise connections for Shenzhen companies with quality partners in the global supply chain [2]

Group 1 - The third China International Supply Chain Promotion Expo (Chain Expo) showcased innovative products from Guangdong enterprises, highlighting their ability to address market demands and drive industry upgrades [1][2] - The "Shumao Tong" platform developed by Zhuozhi Group aims to solve data fragmentation in traditional foreign trade, improving business processes by 40% and reducing supply chain costs by 15% to 20% [1] - Betterray New Materials' long-lasting graphite battery materials have been designed to meet the urgent market demand for longer-lasting and safer batteries, significantly enhancing lithium-ion insertion/extraction efficiency [1] Group 2 - Guangdong enterprises are actively applying new technologies such as AI to predict market trends, with products like BGI's "GenSIRO-16 Lingxi" high-throughput gene detection platform integrating AI into bioinformatics [2] - The Chain Expo has facilitated the establishment of an enterprise overseas promotion alliance, integrating resources from market research to cross-border payments, transforming intentions into tangible collaborations [2][3] - The Chain Expo serves as a key platform for promoting global industrial chain collaborative innovation, enhancing China's supply chain status, and supporting the development of small and medium-sized enterprises [3]

Core Viewpoint - The 2025 Global MedTech Conference showcased advancements in medical technology innovation and clinical application, highlighting the achievements of Chinese medical technology companies and teams in key areas such as equipment, service systems, and research transformation [2][23]. Summary by Categories 2025 Global Medical Technology Innovation Awards - The awards included three categories: Technology Innovation Award, Innovation Service Award, and Innovation Transformation Award, recognizing significant contributions from Chinese medical technology enterprises [2][23]. Technology Innovation Award Winners - **Kaili Medical**: Recognized for breakthroughs in ultrasound endoscopy, including the EG-UR5 ultrasound endoscope, which received EU CE certification in 2019 and NMPA approval in 2021, making China the second country with independent intellectual property rights in this technology [8]. - **SinoVision**: Awarded for the OmegaCT One, the world's first ultra-large aperture whole-body spiral CT system, which provides new 3D spatial anatomical information for various medical disciplines [10]. - **Karl Storz**: Lauded for the IMAGE1 S Rubina imaging system, which integrates 4K/3D/NIR fluorescence imaging technology, enhancing surgical precision and anatomical recognition [11]. - **Zhongke Ruiyi**: Acknowledged for developing an intelligent platform for brain health diagnosis and intervention, with over 10 products and 7 NMPA registrations [12]. - **Hua Rui Bo Shi**: Recognized for the Infivision 1900, the world's first commercial 3D electrical impedance imaging device for non-invasive lung monitoring [14]. Innovation Service Award Winners - **Tonghe Litai**: Provided comprehensive preclinical research services, assisting in the successful market registration of innovative medical products [16]. - **Xiyi Medical**: Offered one-stop services for medical device internationalization, helping over 80 projects achieve successful overseas market entry [18]. - **Tsinghua Innovation Star**: Supported medical technology enterprises through a full-process ecosystem service, fostering innovation and commercialization [19]. Innovation Transformation Award Winners - **Lu Hongzhou**: Recognized for developing non-contact health monitoring technologies, including the P20i device for multi-parameter monitoring [20]. - **Wang Yu**: Awarded for creating the world's first intelligent fracture reduction robot, enhancing surgical precision and efficiency [21]. - **Xu Boling**: Acknowledged for leading the development of the MoyoAssist® artificial heart, the first of its kind approved in China, addressing critical care needs [22]. Conclusion - The awarded companies and individuals demonstrated significant advancements in medical technology, showcasing China's progress towards a more systematic, pragmatic, and globally aware development phase in the industry [23].

Investment Rating - Industry investment rating: Stronger than the market (maintained) [1][23] Core Viewpoints - The demand for medical equipment bidding continues to be strong, with a significant recovery in procurement activities expected to improve company financial performance [3][5] - The overall market size for medical device bidding in China exceeded 80 billion yuan in the first half of 2025, showing a year-on-year growth of over 60% [3][11] - Major provinces driving the procurement include Liaoning, Hainan, Ningxia, Fujian, and Shanxi, with imaging equipment being the core focus of upgrades [3][5] Summary by Sections Market Trends - The procurement scale for medical devices has remained high since 2025, with June procurement figures showing significant year-on-year increases across various categories, such as ultrasound (1.391 billion yuan, +49%), CT (1.938 billion yuan, +59%), and MRI (1.531 billion yuan, +64%) [4][12][15] - The bidding recovery is evident, with monthly procurement figures for 2025 showing consistent growth, despite a slight slowdown in June [3][11] Company Performance - Leading companies are expected to benefit significantly from the recovery in equipment bidding, with firms like Mindray Medical projecting a noticeable recovery in overall performance starting from Q3 2025 [3][5][21] - In June 2025, the bidding amounts for major domestic companies were as follows: Mindray (623 million yuan, +15%), United Imaging (769 million yuan, +35%), and Kaili Medical (102 million yuan, +73%) [4][18] Investment Recommendations - The report suggests focusing on domestic leading enterprises that are enhancing their high-end and intelligent medical equipment layouts, such as Mindray Medical, United Imaging, Kaili Medical, and Aohua Endoscopy [5][21] - The continuous support for equipment updates from government policies is expected to positively impact the industry, with a projected increase in procurement activities [21]

Investment Rating - The industry investment rating is "Outperform the Market" [2][45] Core Insights - The total bidding amount for medical devices in June 2025 reached 12.618 billion yuan, representing a year-on-year growth of 30% and a total of 83.817 billion yuan for the first half of 2025, with an overall year-on-year increase of 64% [3][9][10] Summary by Sections Medical Device Bidding Overview - The medical device bidding amount in June 2025 was 12.618 billion yuan, showing a year-on-year increase of 30% and a quarter-on-quarter decrease of 6% [9] - The cumulative bidding amount for the first half of 2025 was 83.817 billion yuan, with a year-on-year growth of 64% [10] Domestic Brands - Mindray Medical's bidding amount in June 2025 was 623 million yuan, up 15% year-on-year, with a total of 4.258 billion yuan for the first half of 2025, reflecting a 64% increase [16][18] - United Imaging's June 2025 bidding amount was 769 million yuan, a 35% year-on-year increase, totaling 4.841 billion yuan for the first half of 2025, up 53% [13][14] - Aohua Endoscopy's June 2025 bidding amount was 27 million yuan, down 46% year-on-year, with a total of 235 million yuan for the first half of 2025, up 57% [19][20] - Kaili Medical's June 2025 bidding amount was 102 million yuan, a 73% year-on-year increase, totaling 642 million yuan for the first half of 2025, up 115% [22][23] - Shanwaishan's June 2025 bidding amount was 30 million yuan, a 222% year-on-year increase, totaling 186 million yuan for the first half of 2025, up 211% [25][26] - Wandong Medical's June 2025 bidding amount was 222 million yuan, a 416% year-on-year increase, totaling 728 million yuan for the first half of 2025, up 107% [28][29] Imported Brands - Philips' June 2025 bidding amount was 658 million yuan, down 4% year-on-year, with a total of 4.570 billion yuan for the first half of 2025, up 61% [31][32] - Siemens' June 2025 bidding amount was 978 million yuan, a 48% year-on-year increase, totaling 6.074 billion yuan for the first half of 2025, up 60% [34][35] - GE's June 2025 bidding amount was 1.447 billion yuan, a 49% year-on-year increase, totaling 6.736 billion yuan for the first half of 2025, up 56% [37][38]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market this week, with the healthcare services sector leading the gains. The overall A-share market rose by 1.50%, while the biopharmaceutical sector increased by 1.82%, outperforming the market [1][33] - Merck announced a $10 billion acquisition of Verona Pharma to obtain the COPD drug Ohtuvayre, which is expected to be a significant product in the respiratory disease treatment market [2][10] - WuXi AppTec is projected to achieve a 102% increase in net profit for the first half of 2025, with revenues expected to reach 20.799 billion yuan, reflecting a growth of 20.64% [3] Summary by Sections Market Performance - The biopharmaceutical sector's price-to-earnings ratio (TTM) stands at 35.79x, which is at the 77.7 percentile of its historical valuation over the past five years [1][38] - The overall A-share market and various sub-sectors showed positive performance, with healthcare services up by 6.46% [1][33] Key Company Updates - Merck's acquisition of Verona Pharma will provide access to Ohtuvayre, a dual-target PDE3/4 inhibitor approved for COPD maintenance therapy, marking a significant advancement in treatment options [2][10] - Ohtuvayre's sales reached $71 million in Q1 2025, indicating strong market uptake and potential for expansion into other indications [22][24] Company Earnings Forecasts - WuXi AppTec's net profit for H1 2025 is expected to be 8.561 billion yuan, a 101.92% increase, driven by strong operational performance [3] - The report includes earnings forecasts for several companies, with WuXi AppTec and Mindray Medical both rated as "Outperform" [4][42] Investment Recommendations - Mindray Medical is highlighted as a leading domestic medical device company benefiting from new healthcare infrastructure and product upgrades [42] - WuXi AppTec is recognized for its comprehensive service capabilities in the new drug development outsourcing market [42] - Other recommended companies include New Industries, Huatai Medical, and Aibo Medical, each with strong market positions and growth potential [42][43][44]

Fixed Income - Credit spreads are expected to have further compression potential, with most industries showing a slight decrease in credit spreads except for the AA agricultural sector which saw a minor increase of 3 basis points [2][6][8] - The yield on 3-5 year perpetual bonds may gradually approach the interest rates of major banks' 3-5 year fixed deposits, indicating that credit spreads may still have room for compression [2][8] Transportation - The State Post Bureau opposes "involution" competition in the express delivery industry, which may lead to high-quality development opportunities [10][11] - Major express companies like Zhongtong, Yuantong, Yunda, and Shentong have seen a decline in single ticket revenue year-on-year, with decreases of -7.8%, -6.4%, -10.1%, and -6.2% respectively in Q1 2025 [11] Media - The upcoming mid-year report disclosures may present trading opportunities, with high-frequency data expected to maintain an upward trend if no turning points are observed [28] - The gaming sector is highlighted, with major titles from companies like Tencent and Giant Network performing well in the market, indicating potential for value reassessment [30][34] North Exchange - The cultural and IP economy is thriving, with the market size of the national trend economy reaching 2.05 trillion yuan in 2023 and expected to exceed 3 trillion yuan by 2028 [23][24] - The Chinese trend toy market is projected to achieve a compound annual growth rate of 35.11% from 2020 to 2024, surpassing the global average [24] Pharmaceutical - The pharmaceutical index rose by 1.82%, with innovative drug companies showing strong performance, indicating a positive outlook for the sector [6][19] - Business development (BD) transactions are expected to become a regular source of income and profit for traditional pharmaceutical companies, enhancing their international revenue share [19] Overall Market Data - The Shanghai Composite Index closed at 3,519.65, reflecting a year-to-date increase of 7.88% [3] - The North Exchange consumption service sector saw a median stock price change of +1.29%, with 25 companies experiencing increases [25]